MTA1 as negative prognostic marker in vulvar carcinoma.
Cancer survival
Clinicopathological factors
MTA1
Metastasis
Prognosis
Vulvar carcinoma
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
05
12
2022
accepted:
06
01
2023
medline:
24
7
2023
pubmed:
24
1
2023
entrez:
23
1
2023
Statut:
ppublish
Résumé
Vulvar cancer is the fourth most common malignancy of the female genital tract after endometrial, ovarian, and cervical carcinoma and affects mainly elderly women. In 2020 there were registered more than 17,000 deaths worldwide related to vulvar carcinoma. Data about target-based therapies and predictive biomarkers for vulva carcinomas are rare so far. The metastasis-associated gene MTA1 is a transcriptional repressor with a potential effect on cancer. Expression of MTA1 was found to be significantly enhanced in gynecological malignancies as breast or ovarian cancer tissues with advanced cancer stages and higher FIGO grading, indicating an important role of MTA1 in the progression of those tumor entities. Due to the lack of information around MTA1 and its significance regarding vulvar carcinoma, this study focuses on the expression of MTA1 in vulvar carcinoma and its correlation to clinicopathological characteristics and prognosis. A total of 157 paraffin-embedded vulvar cancer tissues were immunohistochemically stained and examined for MTA1 expression by using the immunoreactive score. Subsequently, the values were correlated with clinicopathological parameters. MTA1 was found to be expressed in 94% of the patients in the cytoplasm and 91% in the nucleus. Cytoplasmatic expression of MTA1 was significantly increased in non-keratinizing squamous cell carcinoma and in vulvar carcinoma of the condylomatous type, compared to keratinizing squamous cell carcinoma and vulvar carcinoma of the verrucous type. High MTA1 expression in the nucleus was associated with advanced tumor size as well as higher FIGO grading. In addition, p16 negative vulvar carcinomas showed a higher nuclear expression of MTA1 compared to p16 positive vulvar carcinomas. Suprisingly, Kaplan-Meier analysis showed a significantly lower disease-free survival in tumor samples without a nuclear expression of MTA1. MTA1 was identified as a negative prognostic marker for vulvar carcinoma associated with advanced tumor stage and FIGO grading. A possible explanation could be that the antibody used for this study does not bind to a possible mutation in the C terminal region of MTA leading to negative immunohistochemical staining and this can be correlated with early recurrence in patients with vulvar carcinoma.
Identifiants
pubmed: 36689059
doi: 10.1007/s00432-023-04579-4
pii: 10.1007/s00432-023-04579-4
pmc: PMC10356867
doi:
Substances chimiques
Biomarkers, Tumor
0
Transcription Factors
0
MTA1 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
6191-6201Informations de copyright
© 2023. The Author(s).
Références
J Reprod Med. 2000 Aug;45(8):613-5
pubmed: 10986677
Cancer Biol Ther. 2008 Sep;7(9):1460-7
pubmed: 18719363
Histopathology. 2020 Jan;76(1):128-138
pubmed: 31846523
Int J Gynecol Pathol. 2020 Jul;39(4):391-399
pubmed: 31274700
Am J Pathol. 1998 Dec;153(6):1741-8
pubmed: 9846965
Histopathology. 2017 Aug;71(2):238-246
pubmed: 28257152
Am J Surg Pathol. 2004 May;28(5):638-43
pubmed: 15105653
Cell Cycle. 2006 Apr;5(8):812-7
pubmed: 16627996
Cancer Metastasis Rev. 2009 Jun;28(1-2):151-66
pubmed: 19153669
Int J Oral Maxillofac Surg. 2008 Nov;37(11):1039-46
pubmed: 18640824
J Biol Chem. 1994 Sep 16;269(37):22958-63
pubmed: 8083195
Cancer Metastasis Rev. 2012 Dec;31(3-4):455-67
pubmed: 22733307
Pathology. 2016 Jun;48(4):291-302
pubmed: 27113549
Clin Exp Metastasis. 2009;26(3):215-27
pubmed: 19116762
Mod Pathol. 2008 Mar;21(3):334-44
pubmed: 18192968
CA Cancer J Clin. 2016 Jul;66(4):271-89
pubmed: 27253694
Cancer Metastasis Rev. 2014 Dec;33(4):943-51
pubmed: 25319202
Cancer Metastasis Rev. 2014 Dec;33(4):843-56
pubmed: 25398252
Am J Surg Pathol. 2006 Nov;30(11):1347-56
pubmed: 17063073
J Natl Cancer Inst. 2015 Jan 24;107(3):
pubmed: 25618900
Int J Gynaecol Obstet. 2021 Oct;155(1):43-47
pubmed: 34520062
Gynecol Oncol. 2016 Jan;140(1):8-14
pubmed: 26428940
Int J Mol Sci. 2020 Dec 05;21(23):
pubmed: 33291445
Hum Pathol. 2006 Jun;37(6):656-61
pubmed: 16733204
Int J Cancer. 2017 Sep 15;141(6):1161-1169
pubmed: 28577297
Gynecol Oncol. 2018 Jan;148(1):126-131
pubmed: 29126556
Mol Cell. 1998 Dec;2(6):851-61
pubmed: 9885572
Obstet Gynecol. 2006 May;107(5):1018-22
pubmed: 16648405
Br J Cancer. 1999 Apr;79(11-12):1723-6
pubmed: 10206283
Crit Rev Oncol Hematol. 2012 Apr;82(1):25-39
pubmed: 21601474
J Biol Chem. 2006 Sep 1;281(35):25612-21
pubmed: 16807247
Oncogene. 2004 May 27;23(25):4422-9
pubmed: 15077195
Pathologe. 1987 May;8(3):138-40
pubmed: 3303008